Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and Midazolam, Pitavastatin, and Atorvastatin in Healthy Volunteers

被引：0
|
作者：
Caro, Luzelena [1 ]
Talaty, Jennifer E. [1 ]
Guo, Zifang [2 ]
Reitmann, Christina [3 ]
Fraser, Iain P. [3 ]
Evers, Raymond [4 ]
Swearingen, Dennis [5 ]
Yeh, Wendy W. [3 ]
Butterton, Joan R. [3 ]
机构：
[1] Merck & Co Inc, Clin Drug Metab & Pharmacokinet, Whitehouse Stn, NJ USA
[2] Merck & Co Inc, Early Clin Dev Stat, Whitehouse Stn, NJ USA
[3] Merck & Co Inc, Clin Res, Whitehouse Stn, NJ USA
[4] Merck & Co Inc, Transporter In Vitro Technol, Whitehouse Stn, NJ USA
[5] Celerion, Tempe, AZ USA
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
477
引用
收藏
页码：437A / 438A
页数：2
相关论文
共 50 条
  • [31] Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers
    G. Peytavin
    C. Gautran
    C. Otoul
    A. C. Cremieux
    B. Moulaert
    F. Delatour
    M. Melac
    M. Strolin-Benedetti
    R. Farinotti
    European Journal of Clinical Pharmacology, 2005, 61 : 267 - 273
  • [32] Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers
    Peytavin, G
    Gautran, C
    Otoul, C
    Cremieux, AC
    Moulaert, B
    Delatour, F
    Melac, M
    Strolin-Benedetti, M
    Farinotti, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (04) : 267 - 273
  • [33] Lack of a clinically significant drugdrug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole
    de Kanter, Clara T. M. M.
    Colbers, Angela P. H.
    Blonk, Maren I.
    Verweij-van Wissen, Corrien P. W. G. M.
    Schouwenberg, Bas J. J. W.
    Drenth, Joost P. H.
    Burger, David M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (06) : 1415 - 1422
  • [34] Pharmacokinetic Interaction Between the HCV Protease Inhibitor Boceprevir and Ethinyl Estradiol/Norethindrone
    Lin, Wen Hong
    Feng, Hwa Ping
    Chatterjee, Manash
    Xuan, Fengjuan
    O'Reilly, Terry
    Wagner, John A.
    Butterton, Joan R.
    HEPATOLOGY, 2012, 56 : 1078A - 1079A
  • [35] SAFETY, TOLERABILITY, AND PHARMACOKINETICS ATER SINGLE AND MULTIPLE DOSES OF MK-5172, A NOVEL HCV NS3/4A PROTEASE INHIBITOR WITH POTENT ACTIVITY AGAINST KNOWN RESISTANCE MUTANTS, IN HEALTHY SUBJECTS
    Brainard, Diana M.
    Petry, Amelia
    Anderson, Matt S.
    Mitselos, Anna
    Laethem, Tine
    Heirman, Ingeborg
    Caro, Luzelena
    Stone, Julie A.
    Sun, Peng
    Panorchan, Paul
    Van Bortel, Lucas M.
    Iwamoto, Marian
    Wagner, John A.
    HEPATOLOGY, 2010, 52 (04) : 1216A - 1217A
  • [36] PHARMACOKINETIC INTERACTION BETWEEN ATORVASTATIN AND MEITORMIN AT STEADY-STATE IN HEALTHY KOREAN VOLUNTEERS.
    Choi, H.
    Kim, D.
    Seo, J.
    Ghim, J.
    Koo, Y.
    Shin, J.
    Kim, E.
    Kim, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S40 - S40
  • [37] MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection (vol 23, pg 719, 2014)
    Gentile, I
    Buonomo, A. R.
    Borgia, F.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (07)
  • [38] Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers
    Blonk, Maren
    van Beek, Michiel
    Colbers, Angela
    Schouwenberg, Bas
    Burger, David
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 69 (01) : 44 - 51
  • [39] SAFETY AND ANTIVIRAL ACTIVITY OF MK-5172, A NOVEL HCV N53/4A PROTEASE INHIBITOR WITH POTENT ACTIVITY AGAINST KNOWN RESISTANCE MUTANTS, IN GENOTYPE 1 AND 3 HCV-INFECTED PATIENTS
    Brainard, Diana M.
    Petry, Amelia
    Van Dyck, Kristien
    Nachbar, Robert B.
    De Lepeleire, Inge M.
    Caro, Luzelena
    Stone, Julie A.
    Sun, Peng
    Uhle, Markus
    Wagner, Frank D.
    O'Mara, Edward
    Wagner, John A.
    HEPATOLOGY, 2010, 52 (04) : 706A - 707A
  • [40] MK-5172, A SECOND GENERATION HCV NS3/4A PROTEASE INHIBITOR IS ACTIVE AGAINST COMMON RESISTANCE ASSOCIATED VARIANTS (RAVS) AND EXHIBITS CROSS-GENOTYPE ACTIVITY
    Graham, Donald
    Acosta, Adriana
    Guo, Zhuyan
    Howe, John A.
    Ogert, Robert A.
    Miller, Michael D.
    Hazuda, Daria
    Olsen, David B.
    Ludmerer, Steve
    Strizki, Julie M.
    Barnard, Richard J.
    HEPATOLOGY, 2011, 54 : 543A - 543A
12345